Kontafarma China Holdings Limited provided earnings guidance for the six months ended 30 June 2023. The Group is expected to record a consolidated net profit for the Period of approximately HKD 17.1 million to HKD 25.7 million, compared to the Group's consolidated net loss of approximately HKD 35.1 million for the six months ended 30 June 2022 (after consolidating the Group's loss after tax from continuing operations of approximately HKD 67.5 million and profit after tax from discontinued operation of approximately HKD 32.4 million for the six months ended 30 June 2022).